期刊文献+

上皮性卵巢癌中尿激酶型纤溶酶原激活因子的表达及其与肿瘤血管生成的关系 被引量:2

Relationship between expression of urokinase-type plasminogen activator and tumor angiogenesis in epithelial ovarian carcinoma
下载PDF
导出
摘要 目的探讨尿激酶型纤溶酶原激活因子(uPA)在上皮性卵巢癌组织中的表达及其与肿瘤血管生成的关系。方法采用免疫组化SP法检测uPA在上皮性卵巢癌(n=85)、上皮性卵巢交界性肿瘤(n=16)、上皮性卵巢良性肿瘤(n=39)及正常卵巢组织(n=24)中的表达情况,以CD34标记上皮性卵巢癌中的微血管,采用人工计数测定其微血管密度(MVD),分析uPA表达与MVD的相关性,并对85例上皮性卵巢癌患者进行随访。结果 uPA在上皮性卵巢癌中的阳性表达率最高。uPA及MVD的表达与上皮性卵巢癌的分化程度、临床分期、淋巴转移、大网膜转移及5年生存率有关(P<0.05),且uPA在上皮性卵巢癌中的表达与MVD呈显著正相关(r=0.56,P=0.02)。结论 uPA可促进上皮性卵巢癌的血管生成,并参与肿瘤的发生发展及侵袭转移。uPA表达及MVD可作为判断上皮性卵巢癌侵袭、转移及预后的重要指标。 Objective To explore the expression of urokinase-type plasminogen activator(uPA) in epithelial ovarian carcinoma(EOC) and the relationship of the expression to microvessel density.Methods SP immunohistochemical staining was performed to determine the expression of uPA in ovarian cancer(85 cases),borderline ovarian tumor(16 cases),benign ovarian tumor(39 cases) and normal ovarian tissue(24 cases).Microvessels in ovarian cancer were marked by CD34,and microvessel density(MVD) was determined by direct count.The relationship between uPA and MVD was analyzed.The 85 patients with epithelial ovarian cancer were followed up.Results The highest positive rate of uPA existed in the patients with EOC.There was a correlation between the expression of uPA and MVD and the differentiation of EOC,clinical stage,lymphatic metastasis,omental metastasis,and 5 years survival rate.A significant positive correlation was found between the expression of uPA in EOC and MVD(r=0.56,P=0.02).Conclusion uPA may promote the angiogenesis of EOC,and participate in the occurrence,development,invasion and metastasis of ovarian cancer.The detection of uPA and MVD may be used as an indicator of biological behaviors and prognosis of ovarian cancer.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2011年第6期605-607,共3页 Medical Journal of Chinese People's Liberation Army
关键词 尿纤溶酶原激活物 卵巢肿瘤 免疫组织化学 urinary plasminogen activator ovarian neoplasms immunohistochemistry
  • 相关文献

参考文献11

  • 1宋晖,辛晓燕,赵海波,王德堂,张建芳.靶向survivin基因shRNA抑制宫颈癌裸鼠移植瘤生长的研究[J].解放军医学杂志,2009,34(9):1098-1101. 被引量:2
  • 2Abulafia O, Triest WE, Sherer DM. Angiogenesis in maligncies of the female genital tract[J]. Gynecol Oncol, 1999, 72(2) : 220-231.
  • 3Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast cardnoma[J]. J Natl Cancer Inst, 1992, 84(24): 1875 -1887.
  • 4Gasparini G, Harris AL Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prog nostic tool[J]. J Clin Oncol, 1995, 13(3) : 765-782.
  • 5卢运萍,张阿丽,王世宣,李静,王常玉,马丁.卵巢癌血管内皮生长因子过度表达及肿瘤浸润转移机制的探讨[J].中华妇产科杂志,2002,37(5):294-297. 被引量:25
  • 6Czekay RP, Aertgeerts K, Curriden SA, et al. Plasminogen activa- tor inhibitor-1 detaches cells from extracellular matrices by inactiva ring integrins[J]. J Cell Biol, 2003, 160(5), 781-791.
  • 7Macchione E, Epifano O, Stefanini M, et al. Uroldnase redistribu tion from the secreted to the cell bound fraction in granulose cells of rat preovulatory follicles[J]. Biol Reprod, 2000, 62(4): 895 -903.
  • 8Henic E, Sixt M, Hansson S, et al. EGF stimulated migration in o varian cancer cells is associated with decreased internalization, in- creased surface expression, and increased shedding of the urokinase urasminogen activator receptor []1. Gynecol Oncol, 2006, 101 (1) : 28- 39.
  • 9Kaneko T, Konno H, Baba M, et al. Urokinase-type plaminogen activator expression correlates with tumor angaogenesis and poor out- come in gastric cancer[J]. Cancer Sci, 2003, 94(1): 43-49.
  • 10Shin SJ, Kim KO, Kim MK, et al. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer[J]. Jpn J Clin Oncol, 2005, 35(6): 342-348.

二级参考文献5

共引文献25

同被引文献34

  • 1曾沥琼,杨竹.循环肿瘤细胞在卵巢癌预后中的研究进展[J].医学信息(医学与计算机应用),2014,0(14):604-605. 被引量:2
  • 2Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
  • 3Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Res, 2004, 10(20): 6897-6904.
  • 4Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J]. N EnglJ Med, 2004, 351(8): 781-791.
  • 5Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends[J]. Theranostics, 2013, 3(6): 377- 394.
  • 6Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology[J]. Nature, 2007, 450(7173): 1235-1239.
  • 7Parkinson DR, Dracopoli N, Petty BG, et al. Considerations in the development of circulating tumor cell technology for clinical use[J].J Transl Med, 2012, 10: 138.
  • 8Galletti Gj Sung MS, Vahdat LT, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device[J]. Lab Chip, 2014, 14(1): 14%156.
  • 9Wu S Liu Zj Liu S, et al. Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions[J]. Clin Chem Lab Med, 2014, 52(2): 243-251.
  • 10Aktas B, Kasimir-Bauer S, Heubner M, et al. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy[J]. Int J Gynecol Cancer, 2011, 21(5): 822-830.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部